Chapter title |
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
|
---|---|
Chapter number | 103 |
Book title |
Acute Leukemias II
|
Published in |
Haematology and blood transfusion, January 1990
|
DOI | 10.1007/978-3-642-74643-7_103 |
Pubmed ID | |
Book ISBNs |
978-3-54-050984-4, 978-3-64-274643-7
|
Authors |
Kraft, J, Grille, W, Appelt, M, Hossfeld, D K, Eichelbaum, M, Koslowski, B, Quabeck, K, Kuse, R, Büchner, T, Hiddemann, W, Kraft, J., Grille, W., Appelt, M., Hossfeld, D. K., Eichelbaum, M., Koslowski, B., Quabeck, K., Kuse, R., Büchner, T., Hiddemann, W., Sauerland, M. C., Wendt, F. |
Abstract |
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM). |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 23% |
Student > Master | 3 | 23% |
Other | 1 | 8% |
Professor | 1 | 8% |
Student > Doctoral Student | 1 | 8% |
Other | 2 | 15% |
Unknown | 2 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 54% |
Biochemistry, Genetics and Molecular Biology | 1 | 8% |
Sports and Recreations | 1 | 8% |
Nursing and Health Professions | 1 | 8% |
Unknown | 3 | 23% |